AI's role in lung cancer and mesothelioma care

Artificial intelligence is reshaping how clinicians approach lung cancer and mesothelioma, addressing key challenges in diagnosis and treatment.

Why it matters: 

AI can streamline clinical decision-making, reduce inequality, and minimize pathway delays by automating complex tasks. This is especially crucial in diseases with diagnostic complexity like mesothelioma.

Clinical implications: 

AI enhances multidisciplinary team (MDT) functions, particularly in pathology and radiology.

• Neural networks improve histological classification, prognostication, and treatment response prediction.

• AI supports lung cancer screening and urgent referrals with advanced radiology tools for nodule detection.

Study insights: 

Emerging AI methods reveal new biological insights, assisting in non-invasive marker discovery and enhanced treatment stratification.

• AI-driven radiogenomics integrates molecular and radiomic features for better stratification.

• Tumor segmentation AI aids mesothelioma assessment, overcoming human reader limitations.

The bottom line: 

Harnessing AI in clinical settings is vital for effective lung cancer management and improving diagnostic and predictive capabilities. Future AI research should focus on transparent outputs to support clinician understanding and decision-making.